• Publications
  • Influence
Adenosine receptors: new opportunities for future drugs.
Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery
The Pathogen Box collection is tested against kinetoplastid parasites and malaria life cycle stages in vitro and chemical starting points for malaria, human African trypanosomiasis, Chagas disease, and leishmaniasis drug discovery efforts have been identified.
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond
The results reveal the immense potential for translating the dispersed expertise in biological assays involving human pathogens into drug discovery starting points, by providing open access to new families of molecules, and emphasize how a small additional investment made to help acquire and distribute compounds, and sharing the data, can catalyze drug discovery for dozens of different indications.
Therapeutic applications of glycosidic carbonic anhydrase inhibitors
The clinical use of a highly active carbohydrate‐based CA inhibitor, i.e., topiramate, constitutes an interesting demonstration of the validity of the “sugar approach” for the development of CAIs, and other carbohydrate-based compounds also demonstrate promising potential for the treatment of ophthalmologic diseases.
S-glycosyl primary sulfonamides--a new structural class for selective inhibition of cancer-associated carbonic anhydrases.
A new class of carbonic anhydrase (CA) inhibitor that was designed to selectively target the extracellular domains of the cancer-relevant CA isozymes is presented and valuable insights into ligand-protein interactions of these novel carbohydrate-based sulfonamides with CA are obtained.
Structural Insights into Carbonic Anhydrase IX Isoform Specificity of Carbohydrate-Based Sulfamates
A new class of CA IX inhibitors that comprise a sulfamate as the zinc binding group, a variable linker, and a carbohydrate “tail” moiety are described that present promising candidates for anti-CA IX drugs and the treatment for several aggressive cancer types.
Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors.
An unusual binding mode, with no interactions between the inhibitor molecule and the active site metal ion is previously unobserved for this enzyme class and presents a new opportunity for future drug design campaigns to target a mode of inhibition that differs substantially from classical inhibitors.
A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
The qualitative structure-activity for all derivatives demonstrated that the stereochemical diversity present within the carbohydrate tails effectively interrogated the CA active site topology, to generate several inhibitors that were potent and selective toward hCA IX, an important outcome in the quest for potential cancer therapy applications based on CA inhibition.
Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
A series of benzene sulfonamides containing triazole-O-glycoside tails for evaluation as carbonic anhydrase (CA) inhibitors may prove interesting lead candidates to target tumor-associated CA isozymes, wherein the CA domain is located extracellularly.